Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
The Paradigm Shift in Chronic Hepatitis B Management
On January 7, 2026, the landscape of hepatology reached a historic turning point. GlaxoSmithKline (GSK) announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, successfully achieved its primary endpoints in two landmark Phase III clinical trials: B-Well 1 and B-Well 2. This breakthrough represents more than just a successful clinical trial; it signals a fundamental shift in the treatment paradigm for Chronic Hepatitis B (CHB), moving from the current model of lifelong viral suppression toward a finite, curative therapeutic approach.
For the estimated 250 to 300 million individuals globally living with CHB, the prospect of functional cure—defined as the sustained loss of Hepatitis B surface antigen (HBsAg) and undetectable HBV DNA after the cessation of therapy—has long been the ultimate clinical goal. Historically, this goal was rarely achieved with existing standard-of-care treatments. The B-Well trial results suggest that this goal is now within clinical reach for a significant portion of the patient population.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.